Therapeutic Asset Ratings
204 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Osimertinib
Non Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
P4
BB
(70)
Pyrotinib
Non Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
P4
BB
(70)
Vinorelbine
Non Small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique
P4
BB
(70)
Nivolumab
Non Small Cell Lung Cancer
Fred Hutchinson Cancer Center
P4
BB
(69)
rc48-adc
Non Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
P4
BB
(69)
Tislelizumab
Non Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
P4
BB
(69)
Serplulimab
Non Small Cell Lung Cancer
Tang-Du Hospital
P3
BB
(68)
Ipilimumab
Non Small Cell Lung Cancer
University of Chicago
P3
BB
(67)
su011248
Non Small Cell Lung Cancer
3D Medicines (Sichuan) Co., Ltd.
P4
BB
(66)
Catequentinib
Non Small Cell Lung Cancer
Tang-Du Hospital
P4
BB
(65)
Benmelstobart
Non Small Cell Lung Cancer
The Third Xiangya Hospital of Central South University
P3
BB
(65)
Sunvozertinib
Non Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
P3
BB
(65)
Olaparib
Non Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
P3
B
(63)
Bms-907351
Non Small Cell Lung Cancer
Jun Zhang, MD, PhD
P3
B
(62)
Famitinib
Non Small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University
P3
B
(62)
Hycamtin
Non Small Cell Lung Cancer
Fox Chase Cancer Center
P3
B
(62)
Retifanlimab
Non Small Cell Lung Cancer
University of California, San Diego
P3
B
(62)
TRASTUZUMAB
Non Small Cell Lung Cancer
Fate Therapeutics
P3
B
(62)
Avutometinib
Non Small Cell Lung Cancer
Verastem, Inc.
P2
B
(62)
Defactinib
Non Small Cell Lung Cancer
Verastem, Inc.
P2
B
(62)
azd6244
Non Small Cell Lung Cancer
AstraZeneca
P3
B
(61)
Tucidinostat
Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials
P2
B
(61)
Jinfukang
Non Small Cell Lung Cancer
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
P4
B
(60)
LIDOCAINE
Non Small Cell Lung Cancer
First Affiliated Hospital of Ningbo University
P4
B
(60)
Recaticimab
Non Small Cell Lung Cancer
Hunan Cancer Hospital
P4
B
(60)
Showing 1 to 25 of 204 assets
Previous
Page 1 of 9
Next